NCT04536649 is a Phase 3 clinical trial of Radiotherapy in Glioblastoma, sponsored by Shanghai Proton and Heavy Ion Center.

Who is sponsoring NCT04536649?

NCT04536649 is sponsored by Shanghai Proton and Heavy Ion Center.

What drugs are being tested in NCT04536649?

Interventions in NCT04536649: Radiotherapy.

What condition does NCT04536649 study?

NCT04536649 studies Glioblastoma.

Is NCT04536649 still recruiting?

NCT04536649 is currently status unknown. Last updated 2 September 2020.

Last reviewed 2020-09-02 · How we verify

NCT04536649

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Proton and Heavy Ion Beam Radiation vs. Photon Beam Radiation for Newly Diagnosed Glioblastoma.

Status unknown Phase 3 Last updated 2 September 2020

What this trial tests

Phase 3 trial testing Radiotherapy in Glioblastoma in 369 participants. Status unknown.

Timeline

1 October 2020

Primary endpoint
30 September 2023

30 September 2025

Quick facts

Lead sponsor	Shanghai Proton and Heavy Ion Center
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	369
Start date	1 October 2020
Primary completion	30 September 2023
Estimated completion	30 September 2025
Sites	1 location across China

Drugs / interventions tested

Radiotherapy — full drug profile →

Conditions studied

Glioblastoma — all drugs for Glioblastoma →

Sponsor

Shanghai Proton and Heavy Ion Center — full company profile →

Who can join

Adults 18 to 80, any sex, with Glioblastoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multi-center prospective phase 3 clinical trial to explore the efficacy and side effects of standard-dose photon radiation versus standard-dose proton radiation versus carbon ion boost plus standard proton radiation for newly diagnosed glioblastoma. The patients enrolled will be randomly allocated with 1:1:1 to three group: Control Group, standard-dose photon radiotherapy; Study Group A, standard-dose proton radiotherapy; Study Group B, standard-dose proton radiotherapy plus induction carbon-ion radiotherapy boost. The primary endpoint is overall survival (OS).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Carbon Ion Radiobiology.
Tinganelli W, Durante M. · · 2020 · cited 180× · PMID 33080914 · DOI 10.3390/cancers12103022
Proton versus photon radiation therapy: A clinical review.
Chen Z, Dominello MM, Joiner MC, Burmeister JW. · · 2023 · cited 32× · PMID 37064131 · DOI 10.3389/fonc.2023.1133909
MDM2/X Inhibitors as Radiosensitizers for Glioblastoma Targeted Therapy.
Miles X, Vandevoorde C, Hunter A, Bolcaen J. · · 2021 · cited 26× · PMID 34307171 · DOI 10.3389/fonc.2021.703442
Factors affecting the radiation response in glioblastoma.
Aiyappa-Maudsley R, Chalmers AJ, Parsons JL. · · 2022 · cited 17× · PMID 36325371 · DOI 10.1093/noajnl/vdac156
Review of Novel Surgical, Radiation, and Systemic Therapies and Clinical Trials in Glioblastoma.
Valerius AR, Webb LM, Thomsen A, Lehrer EJ, et al · · 2024 · cited 16× · PMID 39408897 · DOI 10.3390/ijms251910570
Flourish of Proton and Carbon Ion Radiotherapy in China.
Li Y, Li X, Yang J, Wang S, et al · · 2022 · cited 9× · PMID 35237518 · DOI 10.3389/fonc.2022.819905
Charged particle therapy for high-grade gliomas in adults: a systematic review.
Wang Y, Liu R, Zhang Q, Dong M, et al · · 2023 · cited 8× · PMID 36755321 · DOI 10.1186/s13014-022-02187-z
The Majority of United States Citizens With Cancer do not Have Access to Carbon Ion Radiotherapy.
Foote RL, Tsujii H, Imai R, Tsuji H, et al · · 2022 · cited 7× · PMID 35875126 · DOI 10.3389/fonc.2022.954747

Verify or expand the search:

Other trials of Radiotherapy

Trials testing the same drug.

NCT07497607 — Reduced Elective Nodal and CTV Dose for HPV+ Oropharyngeal Squamous Cell Carcinoma · Phase 2 · not yet recruiting
NCT06813664 — ctDNA-Guided CURB for OPD mNSCLC on TKI (CURB-TKI) · Phase 2 · not yet recruiting
NCT07339774 — Traditional Chinese Medicine Preparation Alleviates Radiotherapy-induced Oral Mucositis in Head and Neck Cancer Patients · Phase 2 · recruiting
NCT07353671 — Topical Periplaneta Americana-Derived Meilian Fuxin Liquid for Radiation Dermatitis · Phase 2, PHASE3 · recruiting
NCT07245745 — Prospective Clinical Study Comparing PROMS After Adaptive or Conventional Radiotherapy in Prostate Cancer · NA · recruiting

Other recruiting trials for Glioblastoma

Currently open trials in the same condition.

NCT07284069 — Senicapoc and Perampanel for Newly Diagnosed Glioblastoma · EARLY_PHASE1 · recruiting
NCT05653635 — Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II Study · Phase 2 · recruiting
NCT07480941 — Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma · Phase 1 · recruiting
NCT07448480 — Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas · active not recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Other Shanghai Proton and Heavy Ion Center trials

Trials by the same sponsor.

NCT07135661 — Ultra-Hypofractionated vs. Moderately Hypofractionated Proton Therapy for Early Breast Cancer After Lumpectomy · NA · recruiting
NCT05613452 — Carbon Ion Therapy for Peripheral Non-small Cell Lung Cancer · Phase 2 · recruiting
NCT06677879 — A Prospective Cohort Study of Proton and Photon Therapy for Left-sided Breast Cancer. · Phase 2 · recruiting
NCT05878678 — Prospective Study of Particle Radiotherapy for Breast Cancer With Different Arm Position · Phase 2 · unknown
NCT05692661 — A Dose Escalation Study of Proton and Carbon Ion Irradiation for HER2 Positive and Triple Negative Breast Cancer · Phase 1 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04536649 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Proton and Heavy Ion Center
Last refreshed: 2 September 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04536649.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing